MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.seminoncol.2026.152563

Медицинская библиотека · Seminars in oncology · 2026

Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions.

Suvvari Tarun Kumar, Kocharlakota Sridhar Vns, Mellamputi Jashika, Siripurapu Yamini Subha Lr, Menda Jaideep, Sureddi Teja, Ghatamaneni Vijaykrishna, Veggalam Shreya, Kandi Venkataramana, Tetta Venkata Sarma Jayant

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Gastrointestinal (GI) malignancies such as colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric cancer, esophageal cancer, and hepatocellular carcinoma (HCC) represent a major global cancer burden and remain associated with poor outcomes despite advances in systemic therapy. The limited efficacy of immunotherapy across most GI tumors is largely driven by an immunosuppressive tumor microenvironment (TME), characterized by stromal barriers, low tumor immunogenicity, and immune exclusion. Oncolytic viruses (OVs) have emerged as a novel therapeutic modality with the capacity to induce direct tumor lysis while simultaneously reprogramming the TME.

METHODS

This article is a narrative review and evidence synthesis of oncolytic virotherapy in GI malignancies. Relevant literature was identified through iterative searches of PubMed, Scopus, and ClinicalTrials.gov between January 2010 and May 2026, using combinations of the terms ``oncolytic virus,'' ``oncolytic virotherapy,'' ``clinical trial,'' and disease-specific terms. Priority was given to peer-reviewed early-phase and later-phase clinical trials, mechanistic studies with direct translational relevance to GI cancers, and consensus reviews.

RESULTS

Clinical development of OVs in GI malignancies demonstrates heterogeneous but promising activity. In PDAC, early-phase trials of reovirus- and adenovirus-based platforms have shown safety and immune activation, although efficacy remains limited by stromal and delivery barriers. In CRC, particularly microsatellite-stable disease, OVs such as enadenotucirev and vaccinia-based platforms have demonstrated tumor-selective replication and potential synergy with immune checkpoint inhibitors, especially in liver metastases. HCC represents the most mature model for OV translation within GI cancers, with vaccinia-based platforms such as pexastimogene devacirepvec (Pexa-Vec) demonstrating immune activation despite mixed survival outcomes in late-phase trials. In gastric and esophageal cancers, clinical evidence remains limited but a small number of early-phase studies of telomerase-selective and vaccinia-based OV platforms have demonstrated feasibility, safety, and preliminary biological activity.

CONCLUSIONS

OVs are evolving from experimental cytolytic agents into immunomodulatory platforms within GI oncology. Their clinical success will depend on overcoming anatomical and immunological barriers unique to the GI tract, optimizing delivery approaches, and integrating biomarker-driven patient selection. HCC provides a critical proof-of-concept within GI malignancies, offering translational insights applicable across other tumor types.

Для цитирования: Suvvari Tarun Kumar, Kocharlakota Sridhar Vns, Mellamputi Jashika, Siripurapu Yamini Subha Lr, Menda Jaideep, Sureddi Teja, Ghatamaneni Vijaykrishna, Veggalam Shreya, Kandi Venkataramana, Tetta Venkata Sarma Jayant. Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions.. Seminars in oncology. 2026. DOI: 10.1016/j.seminoncol.2026.152563.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.